These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37370184)

  • 21. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivabradine: Role in the Chronic Heart Failure Armamentarium.
    Psotka MA; Teerlink JR
    Circulation; 2016 May; 133(21):2066-75. PubMed ID: 27217432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ivabradine (Corlanor) for heart failure.
    Med Lett Drugs Ther; 2015 May; 57(1469):75-6. PubMed ID: 25989196
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
    Chow SL; Page RL; Depre C
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of ivabradine hydrochloride in hemodialysis patients with chronic heart failure.
    Kawasaki S; Sakai Y; Harasawa S; Inatsu A; Kubota Y; Hirama A; Kashiwagi T; Iwabu M
    Ther Apher Dial; 2024 Jun; 28(3):354-363. PubMed ID: 38199237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.
    Rohm I; Kretzschmar D; Pistulli R; Franz M; Schulze PC; Stumpf C; Yilmaz A
    J Immunol Res; 2016; 2016():6949320. PubMed ID: 27822484
    [No Abstract]   [Full Text] [Related]  

  • 27. [Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?].
    Kanorskiy SG; Borisenko YV
    Kardiologiia; 2018 Jun; 58(6):85-89. PubMed ID: 30362441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
    Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
    Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivabradine as adjuvant treatment for chronic heart failure.
    Benstoem C; Kalvelage C; Breuer T; Heussen N; Marx G; Stoppe C; Brandenburg V
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013004. PubMed ID: 33147368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.
    Deedwania P
    Drugs; 2013 Sep; 73(14):1569-86. PubMed ID: 24065301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ivabradine: Heart Failure and Beyond.
    Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of heart rate control in chronic heart failure with reduced ejection fraction.
    Grande D; Iacoviello M; Aspromonte N
    Heart Fail Rev; 2018 Jul; 23(4):527-535. PubMed ID: 29687317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
    Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
    Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
    Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.
    Tóth N; Soós A; Váradi A; Hegyi P; Tinusz B; Vágvölgyi A; Orosz A; Solymár M; Polyák A; Varró A; Farkas AS; Nagy N
    Can J Physiol Pharmacol; 2021 Nov; 99(11):1159-1174. PubMed ID: 34636643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart Rate Lowering for Coronary CTA with Ivabradine in End-Stage Liver Disease.
    Tandon R; Agakishiev D; Freese RL; Thompson J; Nijjar PS
    Radiol Cardiothorac Imaging; 2024 Jun; 6(3):e230402. PubMed ID: 38814188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
    Zugck C; Martinka P; Stöckl G
    Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.